Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2007

View Archived Issues

Kosan concludes epothilone agreement with Roche and reveals clinical plans for KOS-1584

Novel rexinoid compound with promising anticancer activity in experimental breast and lung cancer

ENMD-1198 metabolism, pharmacokinetics studied in humans

Escalating doses of CR011-vcMMAE assessed in melanoma patients

Results of TRITON TIMI-38 trial and plans for TRILOGY ACS trial of prasugrel presented

Manhattan administers first dose in phase IIa study of topical PTH (1-34) for psoriasis

FDA approves Oragenics' IND submission for SMaRT Replacement Therapy for tooth decay

Arete initiates phase I clinical trial of AR-9281 for hypertension

Neurocrine enters Japanese licensing agreement with Dainippon Sumitomo Pharma for indiplon

Seattle Genetics initiates phase Ib clinical trial of SGN-40 for multiple myeloma

Poniard initiates phase II trial of picoplatin for metastatic colorectal cancer

Progen receives fast track status and plans to initiate phase III trial for PI-88 for liver cancer

Regado enrolls first patient in phase IIa clinical study of REG-1 anticoagulation system

FDA grants orphan drug designation to AVI BioPharma's AVI-4658

Discovery Laboratories formally responds to FDA's April 2006 approvable letter for Surfaxin

Amira completes phase I trial of AM-103 and initiates phase II trial for AM-803

Palatin initiates human trials for the treatment of congestive heart failure

Protox presents positive final data from PRX-302 prostate cancer study

SkyePharma completes phase III safety study of Flutiform for the treatment of asthma

Viveta Triumph-1 trial meets primary endpoint

Positive phase IIa results reported for MEM-3454 in Alzheimer's disease

Theravance initiates phase II program for MABA compound in COPD

Recent patents disclose novel agents for metabolic diseases

Levetiracetam may prevent seizures in Alzheimer's disease patients

TMC-278 effects on lipids, coadministration with atorvastatin reported

Studies describe raltegravir resistance, pharmacokinetics, efficacy

Nicastrin-targeting antibody for cancer and Alzheimer's disease

NS-4591 shows in vivo activity for the treatment of overactive bladder

Vernalis presents new FAAH inhibitor with in vivo antinociceptive activity at the SfN meeting

Preclinical evaluation of Abbott calpain inhibitor points to potential in neurodegenerative disorder

New treatment option for cachexia disclosed in recent GSK patent

Novel therapeutics for allergic and respiratory disorders described in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...